Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):1–12.

Article  Google Scholar 

Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol. 2020;11:604.

Article  PubMed  PubMed Central  Google Scholar 

Vanoli F, Mantegazza R. Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics. 2022;19(3):897–910.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verschuuren JJGM, Palace J, Murai H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189–202.

Article  CAS  PubMed  Google Scholar 

Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021;96(3):114–22.

Article  PubMed  PubMed Central  Google Scholar 

US Food & Drug Administration. SOLIRIS® (eculizumab) injection, for intravenous use: US prescribing information. 2020. https://www.accessdata.fda.gov. Accessed 3 Apr 2023.

European Medicines Agency. Soliris (eculizumab): EU summary of product characteristics. 2022. https://www.ema.europa.eu. Accessed 3 Apr 2023.

Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4): e0195909.

Article  PubMed  PubMed Central  Google Scholar 

Alexion Pharmaceuticals Inc. ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use: US prescribing information. 2022. https://www.accessdata.fda.gov. Accessed 3 Apr 2023.

European Medicines Agency. Ultomiris (ravulizumab): EU summary of product characteristics. 2022. https://www.ema.europa.eu. Accessed 3 Apr 2023.

Pharmaceuticals and Medical Devices Agency. ULTOMIRIS intravenous infusion 300mg / ULTOMIRIS HI intravenous infusion 300mg/3mL/ULTOMIRIS HI intravenous infusion 1100mg/11mL: Japanese prescribing information. 2022. https://www.pmda.go.jp. Accessed 3 Apr 2023.

Syed YY. Ravulizumab: a review in atypical haemolytic uraemic syndrome. Drugs. 2021;81(5):587–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKeage K, Lyseng-Williamson KA. Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use. Drugs Ther Perspect. 2019;35(9):405–12.

Article  Google Scholar 

Sahelijo L, Mujeebuddin A, Mitchell D, et al. First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals. Blood. 2015;126(23):4777.

Article  Google Scholar 

Vu T, Ortiz S, Katsuno M, et al. Pharmacokinetics and pharmacodynamics of ravulizumab in adults with generalized myasthenia gravis: results from the phase 3 CHAMPION MG study (abstract no. P3-1.002) Neurology. 2022;98(Suppl. 18):850.

Vu T, Meisel A, Mantegazza R, et al. Long-term efficacy and safety of ravulizumab in generalized myasthenia gravis: phase 3 CHAMPION MG study open-label extension [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69–73.

Google Scholar 

Uzawa A, Juel V, Vu T, et al. Efficacy of ravulizumab across sex and age subgroups of patients with generalized myasthenia gravis: a post hoc analysis of the CHAMPION MG study [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69–73.

Google Scholar 

Suzuki S, Howard JF Jr, Vu T, et al. Ravulizumab efficacy in generalized myasthenia gravis by the time from diagnosis [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69–73.

Google Scholar 

Vu T, Meisel A, Mantegazza R, et al. Long-term efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. Muscle Nerve. 2022;65(Suppl. 1):S2–3.

Google Scholar 

Lehnerer S, Jacobi J, Schilling R, et al. Burden of disease in myasthenia gravis: taking the patient’s perspective. J Neurol. 2021;269(6):3050–63.

Article  PubMed  PubMed Central  Google Scholar 

Vitturi BK, Pellegrinelli A, Valerio BCO. Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study. Acta Neurol Belg. 2019;120(1):83–9.

Article  PubMed  Google Scholar 

Parthan A, Johnston K, Govindarajan R. Economic impact of treating generalized myasthenia gravis with ravulizumab vs eculizumab: US payer perspective [abstract no. G45]. J Manag Care Spec Pharm. 2022;28(Suppl. 3-a):S53–4.